{"id":"f-18","rwe":[{"pmid":"41908715","year":"2026","title":"From Imaging to Insight: The Expanding Role of F-18 FDG PET/CT in Multiple Myeloma.","finding":"","journal":"Nuclear medicine and molecular imaging","studyType":"Clinical Study"},{"pmid":"41901624","year":"2026","title":"Investigation of the Effects of Ski Ergometer-Based Training on Respiratory Functions and Isokinetic Muscle Strength in Cross-Country Skiers.","finding":"","journal":"Medicina (Kaunas, Lithuania)","studyType":"Clinical Study"},{"pmid":"41891650","year":"2026","title":"Hyalinizing clear cell carcinoma of the lung: A rare case with long-term follow-up.","finding":"","journal":"Tuberkuloz ve toraks","studyType":"Clinical Study"},{"pmid":"41886628","year":"2026","title":"Dimensionality Engineering of Fluorozirconium Phosphates for Deep-UV-Transparent Crystals with Enhanced Second-Harmonic Generation and Birefringence.","finding":"","journal":"Journal of the American Chemical Society","studyType":"Clinical Study"},{"pmid":"41877892","year":"2026","title":"F18-FDG PET-CT in immune checkpoint inhibitor-associated acute interstitial nephritis: what is the diagnostic value?","finding":"","journal":"Clinical kidney journal","studyType":"Clinical Study"}],"_fda":{"id":"41abd652-7741-45e9-89a8-535a91d57f51","set_id":"08044d8f-036c-4809-997f-dd5180feebe6","openfda":{"nui":["N0000177914","N0000000205"],"unii":["0Z5B2CJX4D"],"route":["INTRAVENOUS"],"spl_id":["41abd652-7741-45e9-89a8-535a91d57f51"],"brand_name":["Fludeoxyglucose F-18"],"spl_set_id":["08044d8f-036c-4809-997f-dd5180feebe6"],"package_ndc":["65857-150-30"],"product_ndc":["65857-150"],"generic_name":["FLUDEOXYGLUCOSE F-18"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FLUDEOXYGLUCOSE F-18"],"pharm_class_epc":["Radioactive Diagnostic Agent [EPC]"],"pharm_class_moa":["Radiopharmaceutical Activity [MoA]"],"manufacturer_name":["Cardinal Health 414, LLC"],"application_number":["ANDA203603"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with Fludeoxyglucose F-18 Injection. It is also not known whether Fludeoxyglucose F-18 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Consider alternative diagnostic tests in a pregnant woman; administer Fludeoxyglucose F-18 Injection only if clearly needed."],"references":["15 REFERENCES 1. Gallagher B.M., Ansari A., Atkins H., Casella V., Christman D.R., Fowler J.S., Ido T., MacGregor R.R., Som P., Wan C.N., Wolf A.P., Kuhl D.E., and Reivich M. “Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals,” J Nucl Med , 1977; 18, 990-6. 2. Jones S.C., Alavi, A., Christman D., Montanez, I., Wolf, A.P., and Reivich M. “The radiation dosimetry of 2 [F-18] fluoro-2-deoxy-D-glucose in man,” J Nucl Med , 1982; 23, 613-617. 3. Kocher, D.C. “Radioactive Decay Tables: A handbook of decay data for application to radiation dosimetry and radiological assessments,” 1981, DOE/TIC-I 1026, 89. 4. ICRP Publication 53, Volume 18, No. l-4,1987, pages 75-76."],"description":["11 DESCRIPTION 11.1 Chemical Characteristics Fludeoxyglucose F-18 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient 2-deoxy-2-[ 18 F]fluoro-D-glucose has the molecular formula of C 6 H 11 18 FO 5 with a molecular weight of 181.26, and has the following chemical structure: Fludeoxyglucose F-18 Injection is provided as a ready to use sterile, pyrogen free, clear, colorless citrate buffered solution. Each mL contains between 0.74 - 18.5 GBq (20 - 500 mCi/mL) of 2-deoxy-2-[ 18 F]fluoro-D-glucose at the EOS, 4.5 mg of sodium chloride in citrate buffer. The pH of the solution is between 4.5 and 7.5. The solution is packaged in a multiple-dose glass vial and does not contain any preservative. Chemical Structure 11.2 Physical Characteristics Fluorine F-18 has a physical half-life of 109.7 minutes and decays to Oxygen O-18 (stable) by positron decay. The principal photons useful for imaging are the dual 511 keV “annihilation” gamma photons that are produced and emitted simultaneously in opposite directions when the positron interacts with an electron (Table 2). Table 2. Principal Radiation Emission Data for Fluorine F-18 Radiation/Emission % Per Disintegration Mean Energy * Produced by positron annihilation From: Kocher, D.C. Radioactive Decay Tables DOE/TIC-I 1026, 89 (1981) Positron(β+) 96.73 249.8 keV Gamma(±)* 193.46 511.0 keV The specific gamma ray constant (point source air kerma coefficient) for fluorine F-18 is 5.7 R/hr/mCi (1.35 x 10 -6 Gy/hr/kBq) at 1 cm. The half-value layer (HVL) for the 511 keV photons is 4 mm lead (Pb) or 2.9 mm tungsten (W) alloy. The range of attenuation coefficients for this radionuclide as a function of shield thickness is shown in Table 3. For example, the interposition of an 8 mm thickness of Pb or 5.8 mm thickness of W alloy, with a coefficient of attenuation of 0.25, will decrease the external radiation by 75%. Table 3. Radiation Attenuation of 511 keV Photons by Lead (Pb) and Tungsten (W) Alloy Shielding Shield Thickness (Pb) mm Shield Thickness (W) Alloy mm Coefficient of Attenuation 0 0 0.00 4 2.9 0.50 8 5.8 0.25 13 9.4 0.10 26 18.7 0.01 39 27.6 0.001 52 37.4 0.0001 For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 4. Table 4. Physical Decay Chart for Fluorine F-18 Minutes Fraction Remaining * calibration time 0* 1.000 15 0.909 30 0.826 60 0.683 110 0.500 220 0.250 440 0.060"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Fludeoxyglucose F-18 Injection is supplied in a multi-dose, capped 30 mL glass vial containing between 0.74 - 18.5 GBq (20 - 500 mCi/mL), of no carrier added 2-deoxy-2-[F-18] fluoro-D-glucose, at end of synthesis, in approximately 2 - 30 mL. The contents of each vial are sterile, pyrogen-free and preservative-free. NDC 65857-150-30 0.74 - 18.5 GBq (20 - 500 mCi/mL) Receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements for the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States as appropriate. Store the Fludeoxyglucose F-18 Injection vial upright in a lead or tungsten alloy shielded container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). The expiration date and time are provided on the container label. Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS time."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Fludeoxyglucose F-18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatric patients with epilepsy, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined. In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F-18 Injection have not been established in pediatric patients."],"effective_time":"20201204","nursing_mothers":["8.3 Nursing Mothers It is not known whether Fludeoxyglucose F-18 Injection is excreted in human milk. Consider alternative diagnostic tests in women who are breast-feeding. Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding."],"clinical_studies":["14 CLINICAL STUDIES 14.1 Oncology The efficacy of Fludeoxyglucose F-18 Injection in positron emission tomography cancer imaging was demonstrated in 16 independent studies. These studies prospectively evaluated the use of Fludeoxyglucose F-18 in patients with suspected or known malignancies, including non-small cell lung cancer, colo-rectal, pancreatic, breast, thyroid, melanoma, Hodgkin's and non-Hodgkin's lymphoma, and various types of metastatic cancers to lung, liver, bone, and axillary nodes. All these studies had at least 50 patients and used pathology as a standard of truth. The Fludeoxyglucose F-18 Injection doses in the studies ranged from 200 MBq to 740 MBq with a median and mean dose of 370 MBq. In the studies, the diagnostic performance of Fludeoxyglucose F-18 Injection varied with the type of cancer, size of cancer, and other clinical conditions. False negative and false positive scans were observed. Negative Fludeoxyglucose F-18 Injection PET scans do not exclude the diagnosis of cancer. Positive Fludeoxyglucose F-18 Injection PET scans cannot replace pathology to establish a diagnosis of cancer. Non-malignant conditions such as fungal infections, inflammatory processes and benign tumors have patterns of increased glucose metabolism that may give rise to false-positive scans. The efficacy of Fludeoxyglucose F-18 Injection PET imaging in cancer screening was not studied. 14.2 Cardiology The efficacy of Fludeoxyglucose F-18 Injection for cardiac use was demonstrated in ten independent, prospective studies of patients with coronary artery disease and chronic left ventricular systolic dysfunction who were scheduled to undergo coronary revascularization. Before revascularization, patients underwent PET imaging with Fludeoxyglucose F-18 Injection (74 - 370 MBq, 2 - 10 mCi) and perfusion imaging with other diagnostic radiopharmaceuticals. Doses of Fludeoxyglucose F-18 Injection ranged from 74 - 370 MBq (2 - 10 mCi). Segmental, left ventricular, wall-motion assessments of asynergic areas made before revascularization were compared in a blinded manner to assessments made after successful revascularization to identify myocardial segments with functional recovery. Left ventricular myocardial segments were predicted to have reversible loss of systolic function if they showed Fludeoxyglucose F-18 accumulation and reduced perfusion (i.e., flow-metabolism mismatch). Conversely, myocardial segments were predicted to have irreversible loss of systolic function if they showed reductions in both Fludeoxyglucose F-18 accumulation and perfusion (i.e., matched defects). Findings of flow-metabolism mismatch in a myocardial segment may suggest that successful revascularization will restore myocardial function in that segment. However, false-positive tests occur regularly, and the decision to have a patient undergo revascularization should not be based on PET findings alone. Similarly, findings of a matched defect in a myocardial segment may suggest that myocardial function will not recover in that segment, even if it is successfully revascularized. However, false-negative tests occur regularly, and the decision to recommend against coronary revascularization, or to recommend a cardiac transplant, should not be based on PET findings alone. The reversibility of segmental dysfunction as predicted with Fludeoxyglucose F-18 PET imaging depends on successful coronary revascularization. Therefore, in patients with a low likelihood of successful revascularization, the diagnostic usefulness of PET imaging with Fludeoxyglucose F-18 Injection is more limited. 14.3 Neurology In a prospective, open label trial, Fludeoxyglucose F-18 Injection was evaluated in 86 patients with epilepsy. Each patient received a dose of Fludeoxyglucose F-18 Injection in the range of 185-370 MBq (5-10 mCi). The mean age was 16.4 years (range: 4 months - 58 years; of these, 42 patients were less than 12 years and 16 patients were less than 2 years old). Patients had a known diagnosis of complex partial epilepsy and were under evaluation for surgical treatment of their seizure disorder. Seizure foci had been previously identified on ictal EEGs and sphenoidal EEGs. Fludeoxyglucose F-18 Injection PET imaging confirmed previous diagnostic findings in 16% (14/87) of the patients; in 34% (30/87) of the patients, Fludeoxyglucose F-18 Injection PET images provided new findings. In 32% (27/87), imaging with Fludeoxyglucose F-18 Injection was inconclusive. The impact of these imaging findings on clinical outcomes is not known. Several other studies comparing imaging with Fludeoxyglucose F-18 Injection results to subsphenoidal EEG, MRI and/or surgical findings supported the concept that the degree of hypometabolism corresponds to areas of confirmed epileptogenic foci. The safety and effectiveness of Fludeoxyglucose F-18 Injection to distinguish idiopathic epileptogenic foci from tumors or other brain lesions that may cause seizures have not been established."],"pharmacodynamics":["12.2 Pharmacodynamics Fludeoxyglucose F-18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F-18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration. In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity, or (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F-18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F-18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F-18. In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F-18 accumulates in the myocyte and can be detected with PET imaging. In the brain, cells normally rely on aerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure, glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic."],"pharmacokinetics":["12.3 Pharmacokinetics Distribution: In four healthy male volunteers, receiving an intravenous administration of 30 seconds in duration, the arterial blood level profile for Fludeoxyglucose F-18 decayed triexponentially. The effective half-life ranges of the three phases were 0.2-0.3 minutes, 10-13 minutes with a mean and standard deviation (STD) of 11.6 (±) 1.1 min, and 80-95 minutes with a mean and STD of 88 (±) 4 min. Plasma protein binding of Fludeoxyglucose F-18 has not been studied. Metabolism: Fludeoxyglucose F-18 is transported into cells and phosphorylated to [ 18 F]-FDG-6- phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F-18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F-18]fluoro-6-phospho-D-mannose([F-18]FDM-6-phosphate). Fludeoxyglucose F-18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of ClDG are presumed to be similar to Fludeoxyglucose F-18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (ClDG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, ClDG, and ClDM) presumably leave cells by passive diffusion. Fludeoxyglucose F-18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours. Fludeoxyglucose F-18 that is not involved in glucose metabolism in any tissue is then excreted in the urine. Elimination: Fludeoxyglucose F-18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine. Three elimination phases have been identified in the reviewed literature. Within 33 minutes, a mean of 3.9% of the administrated radioactive dose was measured in the urine. The amount of radiation exposure of the urinary bladder at two hours post-administration suggests that 20.6% (mean) of the radioactive dose was present in the bladder. Special Populations: The pharmacokinetics of Fludeoxyglucose F-18 Injection have not been studied in renally-impaired, hepatically impaired or pediatric patients. Fludeoxyglucose F-18 is eliminated through the renal system. Avoid excessive radiation exposure to this organ system and adjacent tissues. The effects of fasting, varying blood sugar levels, conditions of glucose intolerance, and diabetes mellitus on Fludeoxyglucose F-18 distribution in humans have not been ascertained [ see Warnings and Precautions ( 5.2 ) ]."],"adverse_reactions":["6 ADVERSE REACTIONS Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting. Have emergency resuscitation equipment and personnel immediately available. Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Cardinal Health at 1-800-618-2768 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS None None ( 4 )"],"description_table":["
Table 2. Principal Radiation Emission Data for Fluorine F-18
Radiation/Emission% Per DisintegrationMean Energy
* Produced by positron annihilation From: Kocher, D.C. Radioactive Decay Tables DOE/TIC-I 1026, 89 (1981)
Positron(β+)96.73249.8 keV
Gamma(±)*193.46511.0 keV
","
Table 3. Radiation Attenuation of 511 keV Photons by Lead (Pb) and Tungsten (W) Alloy Shielding
Shield Thickness (Pb) mmShield Thickness (W) Alloy mmCoefficient of Attenuation
000.00
42.90.50
85.80.25
139.40.10
2618.70.01
3927.60.001
5237.40.0001
","
Table 4. Physical Decay Chart for Fluorine F-18
MinutesFraction Remaining
* calibration time
0*1.000
150.909
300.826
600.683
1100.500
2200.250
4400.060
"],"drug_interactions":["7 DRUG INTERACTIONS The possibility of interactions of Fludeoxyglucose F-18 Injection with other drugs taken by patients undergoing PET imaging has not been studied."],"mechanism_of_action":["12.1 Mechanism of Action Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F-18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F-18 reflect greater than normal rates of glucose metabolism."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F-18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F-18 reflect greater than normal rates of glucose metabolism. 12.2 Pharmacodynamics Fludeoxyglucose F-18 Injection is rapidly distributed to all organs of the body after intravenous administration. After background clearance of Fludeoxyglucose F-18 Injection, optimal PET imaging is generally achieved between 30 to 40 minutes after administration. In cancer, the cells are generally characterized by enhanced glucose metabolism partially due to (1) an increase in activity of glucose transporters, (2) an increased rate of phosphorylation activity, (3) a reduction of phosphatase activity, or (4) a dynamic alteration in the balance among all these processes. However, glucose metabolism of cancer as reflected by Fludeoxyglucose F-18 accumulation shows considerable variability. Depending on tumor type, stage, and location, Fludeoxyglucose F-18 accumulation may be increased, normal, or decreased. Also, inflammatory cells can have the same variability of uptake of Fludeoxyglucose F-18. In the heart, under normal aerobic conditions, the myocardium meets the bulk of its energy requirements by oxidizing free fatty acids. Most of the exogenous glucose taken up by the myocyte is converted into glycogen. However, under ischemic conditions, the oxidation of free fatty acids decreases, exogenous glucose becomes the preferred myocardial substrate, glycolysis is stimulated, and glucose taken up by the myocyte is metabolized immediately instead of being converted into glycogen. Under these conditions, phosphorylated Fludeoxyglucose F-18 accumulates in the myocyte and can be detected with PET imaging. In the brain, cells normally rely on aerobic metabolism. In epilepsy, the glucose metabolism varies. Generally, during a seizure, glucose metabolism increases. Interictally, the seizure focus tends to be hypometabolic. 12.3 Pharmacokinetics Distribution: In four healthy male volunteers, receiving an intravenous administration of 30 seconds in duration, the arterial blood level profile for Fludeoxyglucose F-18 decayed triexponentially. The effective half-life ranges of the three phases were 0.2-0.3 minutes, 10-13 minutes with a mean and standard deviation (STD) of 11.6 (±) 1.1 min, and 80-95 minutes with a mean and STD of 88 (±) 4 min. Plasma protein binding of Fludeoxyglucose F-18 has not been studied. Metabolism: Fludeoxyglucose F-18 is transported into cells and phosphorylated to [ 18 F]-FDG-6- phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F-18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F-18]fluoro-6-phospho-D-mannose([F-18]FDM-6-phosphate). Fludeoxyglucose F-18 Injection may contain several impurities (e.g., 2-deoxy-2-chloro-D-glucose (ClDG)). Biodistribution and metabolism of ClDG are presumed to be similar to Fludeoxyglucose F-18 and would be expected to result in intracellular formation of 2-deoxy-2-chloro-6-phospho-D-glucose (ClDG-6-phosphate) and 2-deoxy-2-chloro-6-phospho-D-mannose (ClDM-6-phosphate). The phosphorylated deoxyglucose compounds are dephosphorylated and the resulting compounds (FDG, FDM, ClDG, and ClDM) presumably leave cells by passive diffusion. Fludeoxyglucose F-18 and related compounds are cleared from non-cardiac tissues within 3 to 24 hours after administration. Clearance from the cardiac tissue may require more than 96 hours. Fludeoxyglucose F-18 that is not involved in glucose metabolism in any tissue is then excreted in the urine. Elimination: Fludeoxyglucose F-18 is cleared from most tissues within 24 hours and can be eliminated from the body unchanged in the urine. Three elimination phases have been identified in the reviewed literature. Within 33 minutes, a mean of 3.9% of the administrated radioactive dose was measured in the urine. The amount of radiation exposure of the urinary bladder at two hours post-administration suggests that 20.6% (mean) of the radioactive dose was present in the bladder. Special Populations: The pharmacokinetics of Fludeoxyglucose F-18 Injection have not been studied in renally-impaired, hepatically impaired or pediatric patients. Fludeoxyglucose F-18 is eliminated through the renal system. Avoid excessive radiation exposure to this organ system and adjacent tissues. The effects of fasting, varying blood sugar levels, conditions of glucose intolerance, and diabetes mellitus on Fludeoxyglucose F-18 distribution in humans have not been ascertained [ see Warnings and Precautions ( 5.2 ) ]."],"indications_and_usage":["1 INDICATIONS AND USAGE Fludeoxyglucose F-18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F-18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: • Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer ( 1 ). • Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging ( 1 ). • Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures ( 1 ). 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. 1.3 Neurology For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Radiation risks: use smallest dose necessary for imaging ( 5.1 ). • Blood glucose abnormalities: may cause suboptimal imaging ( 5.2 ). 5.1 Radiation Risks Radiation-emitting products, including Fludeoxyglucose F-18 Injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [ see Dosage and Administration ( 2.5 ) ]. 5.2 Blood Glucose Abnormalities In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F-18 Injection administration."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been performed to evaluate the Fludeoxyglucose F-18 Injection carcinogenic potential, mutagenic potential or effects on fertility."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Instruct patients in procedures that increase renal clearance of radioactivity. Encourage patients to: • drink water or other fluids (as tolerated) in the 4 hours before their PET study. • void as soon as the imaging study is completed and as often as possible thereafter for at least one hour. Manufactured and Distributed by: Cardinal Health 414, LLC 7000 Cardinal Place Dublin, OH 43017"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Fludeoxyglucose F-18 Injection emits radiation. Use procedures to minimize radiation exposure. Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description ( 11.2 ) ]. Fludeoxyglucose F-18 Injection emits radiation. Use procedures to minimize radiation exposure. Screen for blood glucose abnormalities. • In the oncology and neurology settings, instruct patients to fast for 4 – 6 hours prior to the drug’s injection. Consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to the drug’s administration ( 5.2 ). • In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to the drug’s injection facilitates localization of cardiac ischemia ( 2.3 ). Aseptically withdraw Fludeoxyglucose F-18 Injection from its container and administer by intravenous injection ( 2 ). The recommended dose: • for adults is 5 – 10 mCi (185 – 370 MBq), in all indicated clinical settings ( 2.1 ). • for pediatric patients is 2.6 mCi in the neurology setting ( 2.2 ). Initiate imaging within 40 minutes following drug injection; acquire static emission images 30 – 100 minutes from time of injection ( 2 ). 2.1 Recommended Dose for Adults Within the oncology, cardiology and neurology settings, the recommended dose for adults is 5 – 10 mCi (185 – 370 MBq) as an intravenous injection. 2.2 Recommended Dose for Pediatric Patients Within the neurology setting, the recommended dose for pediatric patients is 2.6 mCi, as an intravenous injection. The optimal dose adjustment on the basis of body size or weight has not been determined [ see Use in Special Populations ( 8.4 ) ]. 2.3 Patient Preparation • To minimize the radiation absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study. • Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour. • Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [ see Warnings and Precautions ( 5.2 ) ]. Prior to Fludeoxyglucose F-18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 – 6 hours prior to the drug’s injection. • In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 – 75 grams) prior to Fludeoxyglucose F-18 Injection facilitates localization of cardiac ischemia. 2.4 Radiation Dosimetry The estimated human absorbed radiation doses (rem/mCi) to a newborn (3.4 kg), 1-year old (9.8 kg), 5-year old (19 kg), 10-year old (32 kg), 15-year old (57 kg), and adult (70 kg) from intravenous administration of Fludeoxyglucose F-18 Injection are shown in Table 1. These estimates were calculated based on human 2 data and using the data published by the International Commission on Radiological Protection 4 for Fludeoxyglucose 18 F. The dosimetry data show that there are slight variations in absorbed radiation dose for various organs in each of the age groups. These dissimilarities in absorbed radiation dose are due to developmental age variations (e.g., organ size, location, and overall metabolic rate for each age group). The identified critical organs (in descending order) across all age groups evaluated are the urinary bladder, heart, pancreas, spleen, and lungs. Table 1. Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F-18 Injection a Organ Newborn (3.4 kg) 1-year old (9.8 kg) 5-year old (19 kg) 10-year old (32 kg) 15-year old (57 kg) Adult (70 kg) a MIRDOSE 2 software was used to calculate the radiation absorbed dose. Assumptions on the biodistribution based on data from Gallagher et al. 1 and Jones et al. 2 b The dynamic bladder model with a uniform voiding frequency of 1.5 hours was used. * LLI = lower large intestine; ** ULI = upper large intestine Bladder wall b 4.3 1.7 0.93 0.60 0.40 0.32 Heart wall 2.4 1.2 0.70 0.44 0.29 0.22 Pancreas 2.2 0.68 0.33 0.25 0.13 0.096 Spleen 2.2 0.84 0.46 0.29 0.19 0.14 Lungs 0.96 0.38 0.20 0.13 0.092 0.064 Kidneys 0.81 0.34 0.19 0.13 0.089 0.074 Ovaries 0.80 0.8 0.19 0.11 0.058 0.053 Uterus 0.79 0.35 0.19 0.12 0.076 0.062 LLI wall* 0.69 0.28 0.15 0.097 0.060 0.051 Liver 0.69 0.31 0.17 0.11 0.076 0.058 Gallbladder wall 0.69 0.26 0.14 0.093 0.059 0.049 Small intestine 0.68 0.29 0.15 0.096 0.060 0.047 ULI wall** 0.67 0.27 0.15 0.090 0.057 0.046 Stomach wall 0.65 0.27 0.14 0.089 0.057 0.047 Adrenals 0.65 0.28 0.15 0.095 0.061 0.048 Testes 0.64 0.27 0.14 0.085 0.052 0.041 Red marrow 0.62 0.26 0.14 0.089 0.057 0.047 Thymus 0.61 0.26 0.14 0.086 0.056 0.044 Thyroid 0.61 0.26 0.13 0.080 0.049 0.039 Muscle 0.58 0.25 0.13 0.078 0.049 0.039 Bone surface 0.57 0.24 0.12 0.079 0.052 0.041 Breast 0.54 0.22 0.11 0.068 0.043 0.034 Skin 0.49 0.20 0.10 0.060 0.037 0.030 Brain 0.29 0.13 0.09 0.078 0.072 0.070 Other tissues 0.59 0.25 0.13 0.083 0.052 0.042 2.5 Radiation Safety – Drug Handling • Use waterproof gloves, effective radiation shielding, and appropriate safety measures when handling Fludeoxyglucose F-18 Injection to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel and other persons. • Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides. • Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors. Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description ( 11.2 ) ]. • The dose of Fludeoxyglucose F-18 used in a given patient should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed. 2.6 Drug Preparation and Administration • Calculate the necessary volume to administer based on calibration time and dose. • Aseptically withdraw Fludeoxyglucose F-18 Injection from its container. • Inspect Fludeoxyglucose F-18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit. • Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations. • Use Fludeoxyglucose F-18 Injection within 12 hours from the EOS. 2.7 Imaging Guidelines • Initiate imaging within 40 minutes following Fludeoxyglucose F-18 Injection administration. • Acquire static emission images 30 – 100 minutes from the time of injection."],"spl_product_data_elements":["Fludeoxyglucose F-18 Fludeoxyglucose F-18 FLUDEOXYGLUCOSE F-18 FLUDEOXYGLUCOSE F-18 SODIUM CHLORIDE DISODIUM CITRATE SESQUIHYDRATE TRISODIUM CITRATE DIHYDRATE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Multiple-dose glass vial containing 0.74 - 18.5 GBq (20 - 500 mCi/mL) of Fludeoxyglucose F-18 Injection and 4.5 mg of sodium chloride in citrate buffer (approximately 2 - 30 mL volume) for intravenous administration. Multiple-dose glass vial containing 0.74 - 18.5 GBq (20 - 500 mCi/mL) of Fludeoxyglucose F-18 Injection and 4.5 mg of sodium chloride in citrate buffer (approximately 2 - 30 mL volume) for intravenous administration ( 3 )."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Pregnancy Category C: No human or animal data. Consider alternative diagnostics; use only if clearly needed ( 8.1 ). • Nursing mothers: Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding ( 8.3 ). • Pediatric Use: Safety and effectiveness in pediatric patients have not been established in the oncology and cardiology settings ( 8.4 ). 8.1 Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with Fludeoxyglucose F-18 Injection. It is also not known whether Fludeoxyglucose F-18 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Consider alternative diagnostic tests in a pregnant woman; administer Fludeoxyglucose F-18 Injection only if clearly needed. 8.3 Nursing Mothers It is not known whether Fludeoxyglucose F-18 Injection is excreted in human milk. Consider alternative diagnostic tests in women who are breast-feeding. Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding. 8.4 Pediatric Use The safety and effectiveness of Fludeoxyglucose F-18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatric patients with epilepsy, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined. In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F-18 Injection have not been established in pediatric patients."],"dosage_and_administration_table":["
Table 1. Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F-18 Injectiona
OrganNewborn (3.4 kg)1-year old (9.8 kg)5-year old (19 kg)10-year old (32 kg)15-year old (57 kg)Adult (70 kg)
a MIRDOSE 2 software was used to calculate the radiation absorbed dose. Assumptions on the biodistribution based on data from Gallagher et al.1 and Jones et al.2 b The dynamic bladder model with a uniform voiding frequency of 1.5 hours was used. * LLI = lower large intestine; ** ULI = upper large intestine
Bladder wallb4.31.70.930.600.400.32
Heart wall2.41.20.700.440.290.22
Pancreas2.20.680.330.250.130.096
Spleen2.20.840.460.290.190.14
Lungs0.960.380.200.130.0920.064
Kidneys0.810.340.190.130.0890.074
Ovaries0.800.80.190.110.0580.053
Uterus0.790.350.190.120.0760.062
LLI wall*0.690.280.150.0970.0600.051
Liver0.690.310.170.110.0760.058
Gallbladder wall0.690.260.140.0930.0590.049
Small intestine0.680.290.150.0960.0600.047
ULI wall**0.670.270.150.0900.0570.046
Stomach wall0.650.270.140.0890.0570.047
Adrenals0.650.280.150.0950.0610.048
Testes0.640.270.140.0850.0520.041
Red marrow0.620.260.140.0890.0570.047
Thymus0.610.260.140.0860.0560.044
Thyroid0.610.260.130.0800.0490.039
Muscle0.580.250.130.0780.0490.039
Bone surface0.570.240.120.0790.0520.041
Breast0.540.220.110.0680.0430.034
Skin0.490.200.100.0600.0370.030
Brain0.290.130.090.0780.0720.070
Other tissues0.590.250.130.0830.0520.042
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 20-500 mCi/mL Vial Label 20-500 mCi/mL Vial Label NDC # 65857-150-30 30 mL Multiple-Dose Vial Fludeoxyglucose F-18 Injection, USP 20 mCi/mL to 500 mCi/mL @ EOS* Sterile, Non-pyrogenic Date: / / Exp: / / Time: : CAUTION: RADIOACTIVE MATERIAL Each mL Contains: 0.74 GBq to 18.5 GBq (20 mCi/mL to 500 mCi/mL) of no-carrier added Fludeoxyglucose F-18 (2-deoxy-2- [ 18 F]fluoro-D-glucose) @ EOS*; 4.5 mg of sodium chloride in citrate buffer. Do not use if cloudy or if it contains particulate matter. Activity @ EOS* mCi Diagnostic - For Intravenous Use Only Lot #: (Expires 12 hours after EOS*) Store at 25°C (77°F) (see insert) Store upright in a shielded container. Aseptically withdraw and handle doses. [ 18 F] Half-Life = 109.7 min Calculate correct dosage from date and time of calibration. *EOS = End of Synthesis Mfg by Cardinal Health 414, LLC-Dublin, OH 43017 Rx ONLY Principal Display Panel - 20-500 mCi/mL Vial"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Animal studies have not been performed to evaluate the Fludeoxyglucose F-18 Injection carcinogenic potential, mutagenic potential or effects on fertility."]},"tags":[{"label":"Radioactive Diagnostic Agent [EPC]","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Intravenous","category":"route"},{"label":"Injectable","category":"form"},{"label":"Active","category":"status"},{"label":"Oncology","category":"indication"},{"label":"Cardiology","category":"indication"},{"label":"Neurology","category":"indication"},{"label":"malignancy","category":"indication"},{"label":"coronary artery disease","category":"indication"},{"label":"left ventricular dysfunction","category":"indication"},{"label":"3D Imaging Drug","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"240 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"207 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"206 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"182 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"178 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"174 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"174 reports"},{"date":"","signal":"FLUSHING","source":"FDA FAERS","actionTaken":"167 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"163 reports"},{"date":"","signal":"NASOPHARYNGITIS","source":"FDA FAERS","actionTaken":"153 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Hypersensitivity reactions","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Edema","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"}],"contraindications":[],"specialPopulations":{"Lactation":"Use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if Fludeoxyglucose F-18 Injection is administered to a woman who is breast-feeding.","Pregnancy":"Animal reproduction studies have not been conducted with Fludeoxyglucose F-18 Injection. It is also not known whether Fludeoxyglucose F-18 Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Consider alternative diagnostic tests in a pregnant woman; administer Fludeoxyglucose F-18 Injection only if clearly needed.","Paediatric use":"The safety and effectiveness of Fludeoxyglucose F-18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. In pediatric patients with epilepsy, the recommended dose is 2.6 mCi. The optimal dose adjustment on the basis of body size or weight has not been determined. In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F-18 Injection have not been established in pediatric patients."}},"trials":[],"aliases":["F-18 THK-5351","F-18 AV-45","F-18 PMPBB3"],"company":"3D Imaging Drug","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=F-18","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:17:38.487713+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/F-18","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:17:45.545158+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:17:43.753160+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:17:37.597591+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=F-18","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:17:44.064178+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:36.565617+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:36.565645+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:36.565650+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:17:45.978498+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545253/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:45.208130+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203603","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:17:36.565654+00:00"}},"allNames":"fludeoxyglucose f-18","offLabel":[],"synonyms":["Fludeoxyglucose F-18","FLUDEOXYGLUCOSE F-18"],"timeline":[{"date":"20151019","type":"positive","source":"OpenFDA","milestone":"FDA approval (3D Imaging Drug)"}],"approvals":[{"date":"20151019","orphan":false,"company":"3D IMAGING DRUG","regulator":"FDA"}],"brandName":"Fludeoxyglucose F-18","ecosystem":[],"mechanism":{"moaClass":"Radiopharmaceutical Activity [MoA]","modality":"Small Molecule","drugClass":"Radioactive Diagnostic Agent [EPC]","explanation":"Fludeoxyglucose F-18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F-18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [ 18 F] FDG-6-phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F-18 reflect a balance involving glucose transporter, hexokinase and glucose-6-phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F-18 transport and phosphorylation (expressed as the ''lumped constant'' ratio), Fludeoxyglucose F-18 is used to assess glucose metabolism. In comparison to background activity of the spe","oneSentence":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions.","technicalDetail":"Fludeoxyglucose F-18 is a positron-emitting radiopharmaceutical that accumulates in areas of high glucose uptake, such as cancer cells, allowing for imaging using positron emission tomography (PET)."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/McDonnell_Douglas_F%2FA-18_Hornet","title":"McDonnell Douglas F/A-18 Hornet","extract":"The McDonnell Douglas F/A-18 Hornet is an all-weather supersonic, twin-engined, carrier-capable, multirole combat aircraft, designed as both a fighter and ground attack aircraft. Designed by McDonnell Douglas and Northrop, the F/A-18 was derived from the YF-17 that lost against the YF-16 in the United States Air Force's lightweight fighter program. The United States Navy selected the YF-17 for the Navy Air Combat Fighter program, further developed the design and renamed it F/A-18; the United States Marine Corps would also adopt the aircraft. The Hornet is also used by the air forces of several other nations, and formerly by the U.S. Navy's Flight Demonstration Squadron, the Blue Angels."},"commercial":{"launchDate":"2015","_launchSource":"OpenFDA (20151019, 3D IMAGING DRUG)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"F-18\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"F-18\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=f-18","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=f-18","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://en.wikipedia.org/wiki/McDonnell_Douglas_F%2FA-18_Hornet","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-31T10:20:35.393288","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:48.907272+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"f-18","indications":{"approved":[{"name":"Oncology","source":"OpenFDA Label","regulator":"FDA","eligibility":"patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer"},{"name":"Cardiology","source":"OpenFDA Label","regulator":"FDA","eligibility":"patients with coronary artery disease and left ventricular dysfunction"},{"name":"Neurology","source":"OpenFDA Label","regulator":"FDA","eligibility":"patients with foci of epileptic seizures"},{"name":"malignancy","source":"OpenFDA Label","regulator":"FDA"},{"name":"coronary artery disease","source":"OpenFDA Label","regulator":"FDA"},{"name":"left ventricular dysfunction","source":"OpenFDA Label","regulator":"FDA"},{"name":"epileptic seizures","source":"OpenFDA Label","regulator":"FDA"},{"name":"cancer","source":"OpenFDA Label","regulator":"FDA"},{"name":"abnormal glucose metabolism","source":"OpenFDA Label","regulator":"FDA"},{"name":"coronary artery disease and left ventricular dysfunction","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02392429","phase":"PHASE2","title":"FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-20","conditions":["Acute Myeloid Leukemia"],"enrollment":87,"completionDate":"2027-02-13"},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":["Advanced Head and Neck Squamous Cell Carcinoma","Advanced Hypopharyngeal Squamous Cell Carcinoma","Advanced Laryngeal Squamous Cell Carcinoma","Advanced Oral Cavity Squamous Cell Carcinoma","Advanced Oropharyngeal Squamous Cell Carcinoma","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVA Hypopharyngeal Carcinoma AJCC v8","Stage IVA Laryngeal Cancer AJCC v8","Stage IVA Lip and Oral Cavity Cancer AJCC v8","Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IVB Hypopharyngeal Carcinoma AJCC v8","Stage IVB Laryngeal Cancer AJCC v8","Stage IVB Lip and Oral Cavity Cancer AJCC v8","Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"],"enrollment":21,"completionDate":"2026-12-15"},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":["Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8"],"enrollment":636,"completionDate":"2027-01-01"},{"nctId":"NCT05286801","phase":"PHASE1,PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":["Atypical Teratoid/Rhabdoid Tumor","Epithelioid Sarcoma","Kidney Medullary Carcinoma","Malignant Solid Neoplasm","Poorly Differentiated Chordoma","Recurrent Atypical Teratoid/Rhabdoid Tumor","Recurrent Chordoma","Recurrent Epithelioid Sarcoma","Recurrent Kidney Medullary Carcinoma","Recurrent Malignant Solid Neoplasm","Recurrent Rhabdoid Tumor","Refractory Atypical Teratoid/Rhabdoid Tumor","Refractory Chordoma","Refractory Epithelioid Sarcoma","Refractory Kidney Medullary Carcinoma","Refractory Malignant Solid Neoplasm","Refractory Rhabdoid Tumor","Rhabdoid Tumor"],"enrollment":86,"completionDate":"2030-03-31"},{"nctId":"NCT06064097","phase":"PHASE2","title":"A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-25","conditions":["Stage II Nasopharyngeal Carcinoma AJCC v8","Stage III Nasopharyngeal Carcinoma AJCC v8","Stage IV Nasopharyngeal Carcinoma AJCC v8"],"enrollment":50,"completionDate":"2026-12-31"},{"nctId":"NCT07463807","phase":"PHASE1,PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":["Recurrent Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":162,"completionDate":"2026-08-31"},{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":["AIDS-Related Anal Carcinoma","Anal Margin Squamous Cell Carcinoma","Anal Non-Keratinizing Squamous Cell Carcinoma","Anal Squamous Cell Carcinoma","HIV Infection","Rectal Squamous Cell Carcinoma","Stage II Rectal Cancer AJCC v8","Stage IIB Anal Cancer AJCC v8","Stage III Anal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8"],"enrollment":40,"completionDate":"2031-09-15"},{"nctId":"NCT01038778","phase":"PHASE1,PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":["Clear Cell Renal Cell Carcinoma","Metastatic Kidney Carcinoma","Stage III Renal Cell Cancer AJCC v7","Stage IV Renal Cell Cancer AJCC v7"],"enrollment":47,"completionDate":"2027-02-12"},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":["Nodular Lymphocyte Predominant B-Cell Lymphoma","Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma","Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma"],"enrollment":70,"completionDate":"2026-10-31"},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":["Advanced Lung Neuroendocrine Tumor","Functioning Lung Neuroendocrine Tumor","Locally Advanced Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Tumor G1","Lung Neuroendocrine Tumor G2","Metastatic Lung Neuroendocrine Neoplasm","Metastatic Lung Neuroendocrine Tumor","Non-Functioning Lung Neuroendocrine Tumor","Recurrent Lung Neuroendocrine Neoplasm","Unresectable Lung Neuroendocrine Neoplasm","Unresectable Lung Neuroendocrine Tumor"],"enrollment":70,"completionDate":"2033-01-16"},{"nctId":"NCT04981509","phase":"PHASE2","title":"Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-10","conditions":["Hereditary Leiomyomatosis and Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Renal Cell Carcinoma","Sporadic Papillary Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":65,"completionDate":"2027-12-31"},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":["Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"],"enrollment":1875,"completionDate":"2031-04-28"},{"nctId":"NCT04214262","phase":"PHASE3","title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-13","conditions":["Lung Non-Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8"],"enrollment":480,"completionDate":"2028-05-01"},{"nctId":"NCT03952585","phase":"PHASE2,PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":["Basaloid Squamous Cell Carcinoma","Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Oropharyngeal Squamous Cell Carcinoma","Papillary Squamous Cell Carcinoma","Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Squamous Cell Carcinoma"],"enrollment":384,"completionDate":"2026-12-11"},{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":["ACTH","Cushing's Syndrome"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT02398773","phase":"PHASE2","title":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-04","conditions":["HER2/Neu Negative","Progesterone Receptor Negative","Progesterone Receptor Positive","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":99,"completionDate":"2026-03-31"},{"nctId":"NCT00004847","phase":"PHASE1","title":"Diagnosis of Pheochromocytoma","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2000-03-22","conditions":["Pheochromocytoma","Endocrine Disease","Endocrine Diseases"],"enrollment":3000,"completionDate":"2048-11-30"},{"nctId":"NCT05015881","phase":"PHASE2,PHASE3","title":"Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2021-11-01","conditions":["Alcohol Use Disorder (AUD)","Alcohol Drinking"],"enrollment":20,"completionDate":"2027-12"},{"nctId":"NCT00128973","phase":"","title":"Evaluation of Patients With Immune Function Abnormalities","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09-19","conditions":["Chronic Granulomatous Disease (CGD)","X-Linked Severe Combined Immune Deficiency (XSCID)","Leukocyte Adhesion Deficiency 1 (LAD)","Graft Versus Host Disease (cGvHD)"],"enrollment":3500,"completionDate":""},{"nctId":"NCT03648905","phase":"","title":"Clinical Laboratory Evaluation of Chronic Autonomic Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-09-06","conditions":["Parkinson's Disease","Multiple System Atrophy","Autonomic Failure"],"enrollment":89,"completionDate":"2029-12-31"},{"nctId":"NCT01934660","phase":"","title":"Links Between Inflammation and Cardiometabolic Diseases","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-12-02","conditions":["Diabetes Mellitus","Cardiovascular Disease","Healthy Volunteer","Inflammation"],"enrollment":150,"completionDate":""},{"nctId":"NCT05834478","phase":"PHASE3","title":"Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-02-20","conditions":["Withdrawal Symptoms","Opioid Use Disorder","Opioid Use"],"enrollment":103,"completionDate":"2027-04"},{"nctId":"NCT06503146","phase":"PHASE2","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-09","conditions":["Sarcoma","Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)","Mesothelioma","Pheochromocytoma/Paraganglioma (PPGL)","Pancreatic Ductal Adenocarcinoma","Ovarian Cancer","Hepatocellular Carcinoma","Gastric Cancer","Cholangiocarcinoma","Bladder Cancer"],"enrollment":320,"completionDate":"2030-06-01"},{"nctId":"NCT04461509","phase":"PHASE2","title":"High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy","status":"COMPLETED","sponsor":"Alessandro D'Agnolo","startDate":"2021-04-06","conditions":["Prostatic Neoplasms","Genital Neoplasms, Male","Urogenital Neoplasms","Neoplasms by Site","Neoplasms","Genital Diseases, Male","Prostatic Disease"],"enrollment":62,"completionDate":"2024-09-03"},{"nctId":"NCT05617014","phase":"","title":"Alzheimer's Disease Neuroimaging Initiative 4","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2023-06-09","conditions":["Mild Cognitive Impairment","Alzheimer Disease","Dementia"],"enrollment":1500,"completionDate":"2027-07-31"},{"nctId":"NCT04943211","phase":"PHASE3","title":"Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":["Histiocytosis"],"enrollment":150,"completionDate":"2027-06-30"},{"nctId":"NCT00006421","phase":"","title":"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-10-25","conditions":["Breast Cancer"],"enrollment":200,"completionDate":""},{"nctId":"NCT04316117","phase":"PHASE2","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-09-15","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Hormone Receptor Positive Breast Carcinoma","Metastatic Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":138,"completionDate":"2027-08-31"},{"nctId":"NCT04804371","phase":"NA","title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-04","conditions":["Neuroendocrine Tumors"],"enrollment":40,"completionDate":"2027-02-22"},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":["Anal Basaloid Carcinoma","Anal Canal Cloacogenic Carcinoma","Anal Canal Squamous Cell Carcinoma","Anal Margin Squamous Cell Carcinoma","Stage I Anal Cancer AJCC v8","Stage IIA Anal Cancer AJCC v8"],"enrollment":252,"completionDate":"2029-12-31"},{"nctId":"NCT00646022","phase":"","title":"Natural History of Familial Carcinoid Tumor","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-08-25","conditions":["Carcinoid"],"enrollment":1600,"completionDate":""},{"nctId":"NCT06858501","phase":"PHASE2","title":"Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":["Ganglioneuroblastoma","Ganglioneuroblastoma, Nodular","High Risk Neuroblastoma"],"enrollment":84,"completionDate":"2028-12-20"},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":["Hodgkin Lymphoma, Adult","Refractory Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":38,"completionDate":"2033-10-31"},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":["Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Uveal Melanoma","Acral Melanoma","Neuroendocrine Tumors","Paraganglioma","Pheochromocytoma","Adrenocortical Carcinoma","Pancreatic Neuroendocrine Tumor","Thyroid Cancer","Breast Cancer","Lung Adenocarcinoma","Head and Neck Squamous Cell Carcinoma"],"enrollment":18,"completionDate":"2026-10"},{"nctId":"NCT04246437","phase":"PHASE1","title":"[18F]F-DOPA Imaging in Patients With Autonomic Failure","status":"RECRUITING","sponsor":"Daniel Claassen","startDate":"2020-02-04","conditions":["Autonomic Failure","Pure Autonomic Failure","Parkinson Disease","Multiple System Atrophy","Dementia With Lewy Bodies"],"enrollment":40,"completionDate":"2027-02-01"},{"nctId":"NCT03422731","phase":"EARLY_PHASE1","title":"Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-02-15","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia"],"enrollment":74,"completionDate":"2026-11-06"},{"nctId":"NCT03019029","phase":"PHASE1,PHASE2","title":"Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-03-13","conditions":["Amyloidosis"],"enrollment":8,"completionDate":"2022-03-24"},{"nctId":"NCT06667726","phase":"PHASE2","title":"An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-10-01","conditions":["Malignant Brain Neoplasm"],"enrollment":47,"completionDate":"2029-10-08"},{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":["Prostate Adenocarcinoma","Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT04221438","phase":"PHASE2","title":"Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-09-22","conditions":["Melanoma of Unknown Primary","Metastatic Malignant Neoplasm in Lymph Node","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Recurrent Cutaneous Melanoma"],"enrollment":3,"completionDate":"2025-01-31"},{"nctId":"NCT06297590","phase":"PHASE1","title":"A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-08-15","conditions":["Alzheimer Disease"],"enrollment":48,"completionDate":"2027-02"},{"nctId":"NCT04044937","phase":"PHASE2","title":"Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms","status":"COMPLETED","sponsor":"Thomas Hope","startDate":"2018-10-29","conditions":["Intracranial Neoplasm","Low Grade Glioma","Recurrent Glioblastoma","Recurrent World Health Organization (WHO) Grade II Glioma","Recurrent WHO Grade III Glioma"],"enrollment":143,"completionDate":"2024-03-31"},{"nctId":"NCT05876858","phase":"EARLY_PHASE1","title":"EXPLORER Total Body PET/CT Imaging for Myofascial Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2023-06-13","conditions":["Myofascial Pain"],"enrollment":53,"completionDate":"2027-09"},{"nctId":"NCT02740634","phase":"NA","title":"Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2016-05","conditions":["Atypical Alzheimer's Disease","Logopenic Progressive Aphasia (LPA)","Posterior Cortical Atrophy (PCA)","Alzheimer Disease","Alzheimer Disease, Early Onset","Amnestic Disorder","Amnestic Symptoms","Amnestic Mild Cognitive Disorder"],"enrollment":60,"completionDate":"2026-03"},{"nctId":"NCT07164027","phase":"EARLY_PHASE1","title":"Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-11-14","conditions":["Prostate Carcinoma"],"enrollment":30,"completionDate":"2037-01-28"},{"nctId":"NCT06014515","phase":"EARLY_PHASE1","title":"Single-tracer Multiparametric PET Imaging","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2024-02-14","conditions":["Healthy Subjects","Cardiovascular Disease"],"enrollment":60,"completionDate":"2033-08"},{"nctId":"NCT04020978","phase":"NA","title":"Parametric PET of Genitourinary Cancer","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2019-07-16","conditions":["Genitourinary Cancer"],"enrollment":11,"completionDate":"2023-12-15"},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":40,"completionDate":"2028-12-31"},{"nctId":"NCT02379377","phase":"PHASE1","title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-15","conditions":["Adult Hepatocellular Carcinoma","Resectable Hepatocellular Carcinoma","Cholangiocarcinoma","Benign Liver Tumor","Metastases to Liver"],"enrollment":110,"completionDate":"2027-05-31"},{"nctId":"NCT03541889","phase":"PHASE1","title":"REVEAL Biomarkers of Engraftment After Alternative Donor HSCT","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2021-02-05","conditions":["Primary Graft Failure"],"enrollment":56,"completionDate":"2027-11"},{"nctId":"NCT03633955","phase":"PHASE1","title":"Pilot Imaging Study of Leukemia","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2023-01-19","conditions":["Acute Lymphocytic Leukemia","Acute Myeloid Leukemia","Ambiguous Lineage Leukemia or Lymphoma","Myeloma"],"enrollment":60,"completionDate":"2028-04"},{"nctId":"NCT03853915","phase":"NA","title":"FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-23","conditions":["Cervical Cancer"],"enrollment":64,"completionDate":"2027-12-30"},{"nctId":"NCT05436093","phase":"NA","title":"CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-06-23","conditions":["Solid Tumor"],"enrollment":15,"completionDate":"2027-12"},{"nctId":"NCT05321316","phase":"NA","title":"Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-05-31","conditions":["Urothelial Carcinoma"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":["Mantle Cell Lymphoma"],"enrollment":421,"completionDate":"2038-08-31"},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":["Follicular Lymphoma","Non-Hodgkin's Lymphoma","NHL"],"enrollment":33,"completionDate":"2027-01-01"},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":["Prostatic Neoplasm"],"enrollment":49,"completionDate":"2026-12-23"},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":["Biochemically Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":804,"completionDate":"2032-12-31"},{"nctId":"NCT06502691","phase":"PHASE1,PHASE2","title":"[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-02-26","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma"],"enrollment":22,"completionDate":"2030-12-31"},{"nctId":"NCT05710328","phase":"PHASE2","title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-05-10","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","HER2-Positive Breast Carcinoma","Invasive Breast Carcinoma"],"enrollment":235,"completionDate":"2029-12-31"},{"nctId":"NCT06319027","phase":"PHASE2","title":"Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-04-11","conditions":["Glioblastoma, IDH-Wildtype"],"enrollment":100,"completionDate":"2027-05-31"},{"nctId":"NCT05575440","phase":"","title":"Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-22","conditions":["Differentiated Thyroid Gland Carcinoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Papillary Carcinoma"],"enrollment":24,"completionDate":"2028-05-01"},{"nctId":"NCT06103838","phase":"PHASE2","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-25","conditions":["Multiple Myeloma","Newly Diagnosed Multiple Myeloma (NDMM)","Relapsed and/or Refractory Multiple Myeloma (RRMM)"],"enrollment":60,"completionDate":"2031-12-06"},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Unresectable HER2-Negative Breast Carcinoma","Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":60,"completionDate":"2028-06-01"},{"nctId":"NCT07436455","phase":"NA","title":"F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Ankara University","startDate":"2025-11-01","conditions":["Thyroid Cancer","Differentiated Thyroid Cancer"],"enrollment":50,"completionDate":"2026-10-01"},{"nctId":"NCT02125786","phase":"PHASE2","title":"A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-07","conditions":["Ependymoma"],"enrollment":68,"completionDate":"2028-05"},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":["Acute Myeloid Leukemia"],"enrollment":1186,"completionDate":"2029-06-30"},{"nctId":"NCT07285057","phase":"PHASE2","title":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-02-10","conditions":["Prostatic Neoplasms","Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":120,"completionDate":"2027-05-01"},{"nctId":"NCT03759522","phase":"PHASE1","title":"Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2019-02-03","conditions":["Fibromyalgia","Chronic Fatigue Syndrome","Multiple Sclerosis","Healthy"],"enrollment":120,"completionDate":"2028-04"},{"nctId":"NCT05676489","phase":"EARLY_PHASE1","title":"MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":["Healthy Volunteers","Recurrent Glioma","Brain Metastases From Extra-cranial Solid Tumors"],"enrollment":28,"completionDate":"2027-08-30"},{"nctId":"NCT07238322","phase":"","title":"[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-09-22","conditions":["Retrospective Study","Glioma","Brain Neoplasms"],"enrollment":400,"completionDate":"2026-02-23"},{"nctId":"NCT03507257","phase":"","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","status":"RECRUITING","sponsor":"Indiana University","startDate":"2018-04-30","conditions":["Early Onset Alzheimer Disease","Alzheimer Disease","Mild Cognitive Impairment"],"enrollment":850,"completionDate":"2026-05-31"},{"nctId":"NCT06820957","phase":"PHASE2,PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":["CIC-Rearranged Sarcoma","Metastatic Ewing Sarcoma","Metastatic High Grade Sarcoma","Metastatic Undifferentiated Round Cell Sarcoma","Metastatic Undifferentiated Sarcoma, Not Otherwise Specified","Round Cell Sarcoma With EWSR1-non-ETS Fusion","Sarcoma With BCOR Genetic Alterations"],"enrollment":437,"completionDate":"2027-12-31"},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":["Pheochromocytoma","Paraganglioma","Neuroendocrine Tumors","Neuroendocrine Neoplasms"],"enrollment":130,"completionDate":"2033-01-01"},{"nctId":"NCT04689048","phase":"PHASE1","title":"Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-04-04","conditions":["Brain Metastases, Adult","Brain Metastases","Brain Cancer"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT02226276","phase":"NA","title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-01-07","conditions":["Bone Metastases","HER2-positive Breast Cancer","Liver Metastases","Lung Metastases","Recurrent Breast Cancer","Soft Tissue Metastases","Stage IV Breast Cancer"],"enrollment":10,"completionDate":"2026-09-29"},{"nctId":"NCT07285993","phase":"PHASE2","title":"Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET","status":"NOT_YET_RECRUITING","sponsor":"Randy Yeh","startDate":"2026-02-16","conditions":["Breast Cancer","Metastatic Invasive Lobular Breast Cancer"],"enrollment":15,"completionDate":"2027-12-30"},{"nctId":"NCT05775939","phase":"NA","title":"PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-20","conditions":["Lung Carcinoma","Esophageal Carcinoma"],"enrollment":20,"completionDate":"2028-07-01"},{"nctId":"NCT04016818","phase":"EARLY_PHASE1","title":"Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-06","conditions":["Breast Cancer"],"enrollment":20,"completionDate":"2027-12"},{"nctId":"NCT06413355","phase":"PHASE1","title":"FAPI-74 PET/CT in Adults With Fibrosis","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2024-07-16","conditions":["Fibrosis (Morphologic Abnormality)"],"enrollment":45,"completionDate":"2027-07-30"},{"nctId":"NCT04706910","phase":"PHASE3","title":"18F-DOPA II - PET Imaging Optimization","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2021-01-20","conditions":["Congenital Hyperinsulinism","Neuroblastoma","Parkinson Disease","Lewy Body Disease","Neuroendocrine Tumors","Brain Tumor"],"enrollment":800,"completionDate":"2027-12"},{"nctId":"NCT01237054","phase":"PHASE2","title":"Imaging in MGUS, SMM and MM","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-17","conditions":["Multiple Myeloma","Smoldering Multiple Myeloma","Monoclonal Gammopathy of Undetermined Significance"],"enrollment":31,"completionDate":"2011-08-09"},{"nctId":"NCT04273555","phase":"PHASE1,PHASE2","title":"Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-01","conditions":["HER2-positive Breast Cancer"],"enrollment":0,"completionDate":"2028-06-30"},{"nctId":"NCT04459273","phase":"PHASE1","title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-27","conditions":["Bladder Carcinoma","Cervical Carcinoma","Cholangiocarcinoma","Hematopoietic and Lymphoid Cell Neoplasm","Hepatocellular Carcinoma","Malignant Adrenal Gland Neoplasm","Malignant Brain Neoplasm","Malignant Pleural Neoplasm","Malignant Skin Neoplasm","Malignant Solid Neoplasm","Malignant Testicular Neoplasm","Malignant Thymus Neoplasm","Neuroendocrine Neoplasm","Thyroid Gland Carcinoma","Urothelial Carcinoma","Cancer of Unknown Primary Site"],"enrollment":26,"completionDate":"2027-07-01"},{"nctId":"NCT03120624","phase":"PHASE1","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-09-15","conditions":["Metastatic Endometrial Carcinoma","Recurrent Endometrial Adenocarcinoma","Recurrent Endometrial Carcinoma","Recurrent Endometrial Clear Cell Adenocarcinoma","Recurrent Endometrial Endometrioid Adenocarcinoma","Recurrent Endometrial Mixed Cell Adenocarcinoma","Recurrent Endometrial Serous Adenocarcinoma","Recurrent Endometrial Undifferentiated Carcinoma","Recurrent Uterine Corpus Carcinosarcoma","Stage IV Uterine Corpus Cancer AJCC v7"],"enrollment":34,"completionDate":"2028-01-01"},{"nctId":"NCT05781321","phase":"PHASE2","title":"Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-03-23","conditions":["Glioblastoma"],"enrollment":170,"completionDate":"2028-07-02"},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":["Glucose Metabolism","NAFLD (Nonalcoholic Fatty Liver Disease)"],"enrollment":36,"completionDate":"2027-10"},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":["Soft Tissue Sarcoma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT06099093","phase":"PHASE4","title":"Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-04-01","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Metastatic Castration-resistant Prostate Carcinoma"],"enrollment":30,"completionDate":"2026-12-01"},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":15,"completionDate":"2027-12-30"},{"nctId":"NCT02649985","phase":"PHASE1,PHASE2","title":"PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2016-05-02","conditions":["Multiple Sclerosis","Alzheimer's Disease"],"enrollment":250,"completionDate":"2027-12-31"},{"nctId":"NCT04018053","phase":"EARLY_PHASE1","title":"18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2020-02-26","conditions":["Bladder Cancer","Urothelial Carcinoma"],"enrollment":16,"completionDate":"2026-07-01"},{"nctId":"NCT04510220","phase":"PHASE3","title":"9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-21","conditions":["Relapsing Multiple Sclerosis"],"enrollment":10,"completionDate":"2022-12-28"},{"nctId":"NCT07025226","phase":"EARLY_PHASE1","title":"Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-12","conditions":["Glioma"],"enrollment":10,"completionDate":"2027-09-01"},{"nctId":"NCT03860857","phase":"PHASE3","title":"Biomarker Exploration in Aging, Cognition and Neurodegeneration","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2018-05-01","conditions":["Alzheimer Disease","Cognitive Impairment","Cognitive Decline"],"enrollment":300,"completionDate":"2027-12-22"},{"nctId":"NCT04251481","phase":"NA","title":"Diffusion MRI for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-10-16","conditions":["Head Cancer Neck"],"enrollment":16,"completionDate":"2026-04-30"},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":["Estrogen Receptor Positive","Primary or Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":2,"completionDate":"2041-04-30"},{"nctId":"NCT03173924","phase":"PHASE2","title":"18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-06","conditions":["Metastatic Prostate Cancer","Prostatic Neoplasms","Prostate Cancer","Prostatic Cancer","Prostate Neoplasms"],"enrollment":96,"completionDate":"2028-02-06"},{"nctId":"NCT05452889","phase":"EARLY_PHASE1","title":"PET Image in PAH Patients","status":"RECRUITING","sponsor":"Stephen Y. Chan","startDate":"2022-07-11","conditions":["Pulmonary Arterial Hypertension"],"enrollment":71,"completionDate":"2027-02"},{"nctId":"NCT03181867","phase":"PHASE2","title":"18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-03","conditions":["Prostate Neoplasms","Prostatic Cancer","Prostate Cancer","Cancer Of Prostate","Metastatic Prostate Cancer"],"enrollment":800,"completionDate":"2030-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injectable","formulations":[{"form":"INJECTABLE","route":"INTRAVENOUS","productName":""}]},"crossReferences":{"UNII":"0Z5B2CJX4D","SPL_ID":"41abd652-7741-45e9-89a8-535a91d57f51","chemblId":"CHEMBL3545253"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"3D Imaging Drug","relationship":"Original Developer"}],"publicationCount":5462,"therapeuticAreas":["Oncology"],"applicationNumber":"ANDA203777","biosimilarFilings":[],"originalDeveloper":"3D Imaging Drug","recentPublications":[{"date":"2026 Apr","pmid":"41908715","title":"From Imaging to Insight: The Expanding Role of F-18 FDG PET/CT in Multiple Myeloma.","journal":"Nuclear medicine and molecular imaging"},{"date":"2026 Mar 14","pmid":"41901624","title":"Investigation of the Effects of Ski Ergometer-Based Training on Respiratory Functions and Isokinetic Muscle Strength in Cross-Country Skiers.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2026 Mar","pmid":"41891650","title":"Hyalinizing clear cell carcinoma of the lung: A rare case with long-term follow-up.","journal":"Tuberkuloz ve toraks"},{"date":"2026 Mar 26","pmid":"41886628","title":"Dimensionality Engineering of Fluorozirconium Phosphates for Deep-UV-Transparent Crystals with Enhanced Second-Harmonic Generation and Birefringence.","journal":"Journal of the American Chemical Society"},{"date":"2026 Mar","pmid":"41877892","title":"F18-FDG PET-CT in immune checkpoint inhibitor-associated acute interstitial nephritis: what is the diagnostic value?","journal":"Clinical kidney journal"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"3D Imaging Drug","companyId":"3d-imaging-drug","modality":"Small molecule","firstApprovalDate":"2015","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-10-29T00:00:00.000Z","mah":"TRUSTEES UNIV PA","brand_name_local":null,"application_number":"ANDA203801"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-02-27T00:00:00.000Z","mah":"PRECISION NUCLEAR","brand_name_local":null,"application_number":"ANDA204542"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-07T00:00:00.000Z","mah":"PRECISION NUCLEAR","brand_name_local":null,"application_number":"ANDA204546"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-06-24T00:00:00.000Z","mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":"ANDA203777"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-05-21T00:00:00.000Z","mah":"BLUE EARTH","brand_name_local":null,"application_number":"NDA208054"},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"3D IMAGING DRUG","brand_name_local":null,"application_number":null}],"trialStats":{"total":68,"withResults":9},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:48.907272+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}